Abstract

Cancer is a complex devastating disease with enormous treatment challenges, including chemo- and radiotherapeutic resistance. Combination therapy demonstrated a promising strategy to target hard-to-treat cancers and sensitize cancer cells to conventional anti-cancer drugs such as doxorubicin. This study aimed to establish molecular profiling and therapeutic efficacy assessment of chloroquine and/or tioconazole (TIC) combination with doxorubicin (DOX) as anew combination model in MCF-7 breast cancer. The drugs are tested against apoptotic/autophagic pathways and related redox status. Molecular docking revealed that chloroquine (CQ) and TIC could be potential PI3K and ATG4B pathway inhibitors. Combination therapy significantly inhibited cancer cell viability, PI3K/AkT/mTOR pathway, and tumor-supporting autophagic flux, however, induced apoptotic pathways and altered nuclear genotoxic feature. Our data revealed that the combination cocktail therapy markedly inhibited tumor proliferation marker (KI-67) and cell growth, along with the accumulation of autophagosomes and elevation of LC3-II and p62 levels indicated autophagic flux blockage and increased apoptosis. Additionally, CQ and/or TIC combination therapy with DOX exerts its activity on the redox balance of cancer cells mediated ROS-dependent apoptosis induction achieved by GPX3 suppression. Besides, Autophagy inhibition causes moderately upregulation in ATGs 5,7 redundant proteins strengthened combinations induced apoptosis, whereas inhibition of PI3K/AKT/mTOR pathway with Beclin-1 upregulation leading to cytodestructive autophagy with overcome drug resistance effectively in curing cancer. Notably, the tumor growth inhibition and various antioxidant effects were observed in vivo. These results suggest CQ and/or TIC combination with DOX could act as effective cocktail therapy targeting autophagy and PI3K/AKT/mTOR pathways in MCF-7 breast cancer cells and hence, sensitizes cancer cells to doxorubicin treatment and combat its toxicity.

Highlights

  • Cancer is one of the major killers and causes of death worldwide, similar to cardiovascular diseases [1]

  • Previous studies have reported that autophagy inhibition strategies promote cell death in cancer cells which are resistant to many anticancer therapies and may be able to retrieve the sensitivity of those therapies [27]

  • The autophagosomes are implicated as scaffolds to induce apoptosis, which might be exploited as a potential cancer therapy target [28]

Read more

Summary

Introduction

Cancer is one of the major killers and causes of death worldwide, similar to cardiovascular diseases [1]. Pharmaceuticals 2021, 14, 254 obstacles to the successful treatment of various human cancers. Apoptosis and autophagy are types of programmed cell death (PCD) that play a crucial role in maintaining organismal and cell homeostasis quality control mechanisms. It was regarded as a bona fide PCD process involved in the chemotherapy-induced cell death mechanism. Apoptosis is regulated by intracellular and/or extracellular signals; the caspase’s activation is considered a potential therapeutic target against human cancer diseases [3]. Autophagy is a major pathway in all eukaryotic cells and is considered as a multistep process in which cytoplasm, intracellular organelles, and proteins are sequestered through the fusion of autophagosomes with lysosomes forming autolysosomes, with ultimate degradation by lysosomal hydrolases, while autophagy has a crucial role as an emerging cell survival process [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call